Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature

Melissa C. Paoloni, Anita Tandle, Christina Mazcko et al. · 2009

Read Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature by Melissa C. Paoloni, Anita Tandle, Christina Mazcko et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004972.txt.

Description

Pet dogs develop cancers much like human cancers. A new program set out to use that fact. Melissa Paoloni and colleagues launched it in PLOS ONE in 2009. The program is the Comparative Oncology Trials Consortium. It runs preclinical trials in dogs with natural tumors. The National Cancer Institute directs and sponsors the effort.

The consortium's first trial targeted tumor blood vessels. The drug aimed the signal TNF-alpha at the cancer vasculature. Testing in dogs promises more lifelike results than mouse models. It also helps the dogs themselves. The paper reports the launch of this infrastructure. It lays out how canine trials feed into human drug development.

Catalog record

CREATORMelissa C. Paoloni, Anita Tandle, Christina Mazcko et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004972

Browse the full library · About the Tower of Babel